RT Journal Article
SR Electronic
T1 The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.09.15.296228
DO 10.1101/2020.09.15.296228
A1 Robert Konrat
A1 Henrietta Papp
A1 Valéria Szijártó
A1 Tanja Gesell
A1 Gábor Nagy
A1 Mónika Madai
A1 Safia Zeghbib
A1 Anett Kuczmog
A1 Zsófia Lanszki
A1 Zsuzsanna Helyes
A1 Gábor Kemenesi
A1 Ferenc Jakab
A1 Eszter Nagy
YR 2020
UL http://biorxiv.org/content/early/2020/09/15/2020.09.15.296228.abstract
AB Background The COVID-19 pandemic is an enormous threat for healthcare systems and economies worldwide that urgently demands effective preventive and therapeutic strategies. Unlike the development of vaccines and new drugs specifically targeting SARS-CoV-2, repurposing of approved or clinically tested drugs can provide an immediate solution.Methods We applied a novel computational approach to search among approved and clinically tested drugs from the DrugBank database. Candidates were selected based on Shannon entropy homology and predefined activity profiles of three small molecules with proven anti-SARS-CoV activity and a published data set. Antiviral activity of a predicted drug, azelastine, was tested in vitro in SARS-CoV-2 infection assays with Vero E6 monkey kidney epithelial cells and reconstituted human nasal tissue. The effect on viral replication was assessed by quantification of viral genomes by droplet digital PCR.Findings The computational approach with four independent queries identified major drug families, most often and in overlapping fashion anti-infective, anti-inflammatory, anti-hypertensive, anti-histamine and neuroactive drugs. Azelastine, an histamine 1 receptor-blocker, was predicted in multiple screens, and based on its attractive safety profile and availability in nasal formulation, was selected for experimental testing. Azelastine significantly reduced cytopathic effect and SARS-CoV-2 infection of Vero E6 cells with an EC50 of ∼6 μM both in a preventive and treatment setting. Furthermore, azelastine in a commercially available nasal spray tested at 5-fold dilution was highly potent in inhibiting viral propagation in SARS-CoV-2 infected reconstituted human nasal tissue.Interpretations Azelastine, an anti-histamine, available in nasal sprays developed against allergic rhinitis may be considered as a topical prevention or treatment of nasal colonization with SARS-CoV-2. As such, it could be useful in reducing viral spread and prophylaxis of COVID-19. Ultimately, its potential benefit should be proven in clinical studies.Funding provided by the Hungarian government to the National Laboratory of Virology and by CEBINA GmbH.Competing Interest StatementEN, GN and VS are employees and shareholders of CEBINA GmbH. TG is employee and shareholder of Calyxha GmbH. RK receives consultancy fee from Calyxha GmbH and holds shares in the company. This research was funded by CEBINA GmbH, the Hungarian Scientific Research Fund OTKA KH129599, the European Social Fund: Comprehensive Development for Implementing Smart Specialization Strategies at the University of Pecs (EFOP-3.6.1.-16-2016-00004) and the Higher Education Institutional Excellence Program of the Ministry for Innovation and Technology in Hungary, within the framework of the "Innovation for a sustainable life and environment" thematic program of the University of Pecs (TUDFO/47138/2019-ITM).